Preclinical data on simultaneous BCL-2 and PI3K inhibition in Richter’s syndrome, diffuse large B-cell lymphoma (DLBCL), and acute myeloid leukemia (AML) support the hypothesis of synergistic effects of this combinatorial approach [18,19,20]. Here, BCL2 is linked to diffuse large B-cell lymphoma.